Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|June 29, 2024
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatmentsClaudia Fumarola, Silvia La Monica, Mara Bonelli, et al.
Plos One|November 5, 2015
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell LinesMaricla Galetti, Pier Giorgio Petronini, Claudia Fumarola, et al.
Journal of Medicinal Chemistry|February 16, 2010
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portionCaterina Carmi, Andrea Cavazzoni, Stefano Vezzosi, et al.
Cancers|April 26, 2025
Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> 2020, <i>12</i>, 666Andrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, et al.
Cancers|March 18, 2020
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung CancerAndrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, et al.
Biochemical Pharmacology|March 24, 2024
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell linesKamal Eltayeb, Roberta Alfieri, Claudia Fumarola, et al.
Biochemical Pharmacology|April 6, 2010
Functional characterization of gefitinib uptake in non-small cell lung cancer cell linesMaricla Galetti, Roberta R Alfieri, Andrea Cavazzoni, et al.
Frontiers in Oncology|April 12, 2019
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell LinesClaudia Fumarola, Nicole Bozza, Riccardo Castelli, et al.
Plos One|October 30, 2013
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationSilvia La Monica, Cristina Caffarra, Francesca Saccani, et al.
Molecular Cancer|June 6, 2014
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistanceDaniele Cretella, Francesca Saccani, Federico Quaini, et al.
Pageof 6